-
New indications for gastric cancer approved by Mercadon Pembrolizumab in China
On June 25th, Merck announced that its PD-1 inhibitor, Pembrolizumab (trade name: Koreda®), has been approved by the National Medical Products Administration (NMPA) of China for first-line treatm ...- suisuiblue
- 2024-6-25
- 지지
- 반대
- 답장
- 소장
-
New indications for gastric cancer approved by Mercadon Pembrolizumab in China
On June 25, MSD China WeChat official account announced that its PD-1 inhibitor Pabolizumab (trade name: Kereida®) had been approved by the National Drug Administration (NMPA) of China to combine ... -
Merck PD-1 inhibitor CRDA approved as a new indication for melanoma treatment in China
On September 14th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment ...